What's new?

December 03, 2020 03:00 AM Eastern Standard Time   MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announc...

Alderley Park, 2 December 2020 - Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces today that it has conditionally raised c.£25.5 million (before expenses) by way of a placing of 45,603,575 new Ordinary Shares (the "Placing Shares") with both new institutional in...

In-licensing of four clinical-stage product candidates to treat orphan neurological disorders Highly experienced team leverages latest scientific discoveries in neuroscience Financing will advance the development of four clinical-stage product candidates Strong participation from international syndicate of investor...

Company brings together scientific founders with leading-edge expertise in NK cells and leadership team with deep cell therapy experience   Proceeds to advance two lead CAR-NK cell therapy programs based on the company’s TAILWIND™ Platform   November 23, 2020 07:00 AM Eastern Standard Time   CAMBRIDGE, Mass.--(BUSI...

Paris, November 20, 2020 – 07.00 CET– Pixium Vision (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announces it has received approval from the French regulatory health auth...

- Michelin Group and the Canadian firm Pyrowave join forces to accelerate time-to-market for an innovative plastic waste recycling technology. - They agree to fast track the process industrialization. - The purpose of the technology is to increase the rate of sustainable materials not only in Michelin tires, but al...

IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant   TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption...

● Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer ● Initial financing of £4.5M from venture capital syndicate of experienced life sciences investo...

Nov 8, 2020 - Calliditas Therapeutics AB (OMX Nasdaq: CALTX, NASDAQ: CALT) (”Calliditas”) today announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN).

Paris, France, Tuesday, November 3, 2020, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported that...